On Friday, 28 November 2025, CSL Limited (ASX:CSL) edged higher as investors continued to digest a bruising year of profit downgrades, a delayed spin-off, and aggressive cost-cutting – all against the backdrop of a sizeable on-market share buyback and new US investment plans.
CSL share price today: small bounce after a big drawdown
Based on end-of-day data, CSL traded between roughly A$186.6 and A$188.7 and finished the session around A$187.6 per share, with trading volume a little over 138,000 shares. Yahoo Finance
That leaves today’s close only modestly above Thursday’s finish near A$186.2 – a gain of around 0.8% day-on-day – but the bigger story is the longer trend:
- Over the last 12 months, CSL shares are still down roughly 34%. TradingView
- Various analyst and media estimates put the 2025 year-to-date fall at 25–35%, depending on the starting point and intrayear peaks. TechStock²+2The Motley Fool Australia+2
In other words, today’s green print is a small step up in what has been a very rough staircase down.
What’s behind CSL’s tough 2025?
The share price slide did not happen in a vacuum. Several key developments have weighed on sentiment this year:
1. Profit downgrade and delayed spin-off
In late October, CSL shocked the market by:
- Cutting its profit outlook,
- Downgrading FY26 revenue and earnings growth guidance, and
- Delaying the planned spin-off of its vaccine division (Seqirus) amid US market volatility and weaker-than-expected US flu vaccination rates. Reuters+1
The downgrade triggered a brutal reaction:
- CSL shares crashed about 14–16% in a single session, falling to a six-year low after the AGM. Market Index+2raskmedia.com.au+2
That single day reset how the market thinks about CSL’s medium-term growth rate.
2. Shareholder discontent and governance noise
The AGM also brought heightened shareholder scrutiny:
- CSL faced a “shareholder reckoning” after a roughly A$40 billion rout in market value, with investors questioning executive share sales and pay. Capital Brief+1
While none of this changes the underlying science, it does colour investor sentiment – especially for a company historically seen as a “defensive compounder”.
3. Structural changes and cost cutting
Longer-running adjustments also matter:
- CSL has already flagged trimming parts of its R&D division across several global sites and relying more heavily on external partnerships. MarketScreener
- More recently, commentary has highlighted A$500 million in cost-cutting initiatives, aimed at restoring margins over the next few years. The Motley Fool Australia+1
For a growth-at-a-reasonable-price biotech, these moves are framed as efficiency gains by optimists – and as evidence of pressure by pessimists.
Fresh CSL news and commentary on 28 November 2025
While there were no new price-sensitive ASX announcements from CSL itself today, several pieces of analysis and market commentary on 28 November 2025 keep the stock firmly on investors’ radar.
CSL in today’s “2 ASX stocks to turn $100k into $1m”
A Motley Fool Australia article published today named CSL Ltd (ASX:CSL) as one of two stocks that could, in theory, help turn A$100,000 into A$1 million over a long time horizon. The Motley Fool Australia+1
Key takeaways from that piece:
- CSL is described as exactly the sort of “generational wealth creation” stock long-term investors like to own.
- The article acknowledges the 2025 share price slump, citing delays in margin recovery, tariff concerns and uncertainty around the Seqirus spin-off.
- Despite the drawdown, the writer emphasises CSL’s global scale, recurring plasma and vaccine revenues, and history of compounding earnings as reasons some investors still see it as a buy-and-hold candidate.
So, on a day-to-day basis the share price chart looks ugly, but stock-picker commentary continues to place CSL in the “quality franchise on sale” bucket.
Bell Direct: CSL among the week’s most traded stocks
In its Weekly Wrap for 28 November, Bell Direct highlighted CSL Limited (ASX:CSL) as one of the most traded stocks by its clients this week, alongside names like FINEOS and several smaller tech and industrial plays. belldirect.com.au
That tells you two interesting things:
- Retail and adviser-led investors are actively trading the volatility, rather than ignoring the stock.
- CSL’s slump is turning it into a battleground name – some are buying dips, others are cutting losses.
Fresh analysis: “Unlocking insights on CSL Ltd (ASX:CSL) share performance”
A new piece from Kalkine Media, published less than a day ago, zooms in on CSL’s recent share price action and fundamentals. Kalkine Media
The article notes that:
- Revenue growth and profitability remain broadly supportive over the medium term.
- CSL’s financial health underpins its ability to keep investing and maintain operations despite short-term margin pressure.
- The stock continues to attract attention from long-term, fundamentals-driven investors, who are watching valuation, growth guidance and the buyback closely.
Together, today’s commentary paints a picture of a company in the middle of a reset – not abandoned, but no longer treated as an untouchable market darling.
Corporate actions: buyback and expansion plans
Ongoing on-market share buyback
One of the most important supports under the share price right now is CSL’s sizeable buyback:
- The company has been issuing frequent “Update – Notification of buy-back – CSL” announcements through November, most recently on 26 November 2025, confirming continued on-market purchases of its own shares. CSL Limited+2Intelligent Investor+2
This works like a slow, mechanical bid in the market:
- It absorbs some selling pressure,
- Signals that management believes the stock is undervalued, and
- Incrementally boosts earnings per share over time by shrinking the share count.
Of course, a buyback only makes sense if the underlying business can support it – which leads us to CSL’s investment plans.
US$1.5 billion investment in US plasma therapy manufacturing
In mid-November, CSL announced it will invest around US$1.5 billion in the United States to expand manufacturing capacity for plasma-derived therapies. PublicNow
Highlights from that announcement:
- The investment will support long-term demand for key plasma products, a core profit driver for CSL Behring.
- It reinforces CSL’s status as a global leader in plasma-based medicines, not just a local Australian healthcare stock.
This sort of capex doesn’t rescue next quarter’s earnings, but it does support the thesis that the current sell-off is cyclical and execution-related, not an existential threat to the franchise.
Guidance, outlook and what analysts are saying
CSL has tried to reframe expectations after October’s downgrade:
- Recent commentary from management has pointed to mid single-digit revenue growth beyond FY26 and high single-digit NPAT (net profit after tax) growth beyond that period, along with continued dividends. MarketScreener
On the market side:
- TradingView data shows CSL shares are down about 34% over the past year, but analysts’ 12-month price targets still span roughly A$199 to A$282, implying upside from current levels if the company can deliver on its reset guidance. TradingView
On income:
- Dividend data collated by DividendMax suggests a current dividend yield of around 2.4%, with the latest final dividend of A$2.4508 per share paid in October 2025. DividendMax+1
So the broad analyst consensus can be summarised as:
“The growth rate is lower than the glory days, but this is still a highly profitable global healthcare business trading at a discount to its own history.”
Whether that’s enough to overcome sentiment damage is what the market is trying to price, day by day.
Key risks investors are still watching
Even after today’s mild bounce, several uncertainties hang over CSL:
- Vaccine volumes and US flu demand – A key trigger for the recent downgrade was weaker-than-expected US vaccination rates. If that persists, it could keep pressure on margins and growth. Reuters+1
- Seqirus spin-off timing and structure – Delaying the spin-off may be sensible in volatile markets, but investors will want clarity on when and how it proceeds. Reuters+1
- Execution on cost-cutting and R&D reshaping – Trimming internal R&D and relying more on external partnerships introduces execution risk: get it right and margins improve; get it wrong and the innovation pipeline suffers. MarketScreener+1
- Regulation and pricing – As with all plasma and vaccine players, CSL faces regulatory, reimbursement and political risks in major markets, from the US to Europe.
These are not new risks for a global biotech, but the margin for error is smaller when growth has already been dialled down.
What today’s move could mean for CSL investors
Today’s modest gain around A$187–188 doesn’t change the big picture on its own. But taken together with:
- Active buyback activity,
- A pipeline of capex and expansion in US plasma therapies,
- Ongoing interest from long-term stock pickers who still view CSL as a structural compounder, and
- A valuation reset after a 25–35% fall in 2025,
it does suggest the stock may be moving from “capitulation” towards “price discovery” – the messy phase where the market tries to work out what a slower-growing, still-profitable CSL is actually worth.
For short-term traders, CSL remains a volatile large-cap healthcare name closely linked to news on guidance, vaccination trends and buyback updates.
For long-term investors, the key questions now are:
- Do you believe management can hit the new, lower guidance and restore margin momentum?
- Are today’s prices adequately compensating you for the remaining risks in vaccines, plasma collection and R&D restructuring?
